Hana Bio to license chemo drugs from Inex
San Francisco, USA-based Hana Biosciences says it has signed a letter of intent to license, develop and commercialize three novel targeted chemotherapy drug candidates from Canadian firm Inex Pharmaceuticals. The compounds in question are Marqibo (sphingosomal vincristine), sphingosomal vinorelbine and sphingosomal topotecan, the first of which has already demonstrated efficacy in the treatment of non-Hodgkin's lymphoma.
Hana will pay a total of $11.5 million made up of cash shares and stock to Inex on closure of the transaction. In addition, Hana has agreed to pay a further $30.5 million in shares, based on the achievement of regulatory approvals and clinical development milestones.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze